Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TEZEPELUMAB Cause Chronic obstructive pulmonary disease? 34 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 34 reports of Chronic obstructive pulmonary disease have been filed in association with TEZEPELUMAB (TEZSPIRE). This represents 3.1% of all adverse event reports for TEZEPELUMAB.

34
Reports of Chronic obstructive pulmonary disease with TEZEPELUMAB
3.1%
of all TEZEPELUMAB reports
2
Deaths
22
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From TEZEPELUMAB?

Of the 34 reports, 2 (5.9%) resulted in death, 22 (64.7%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TEZEPELUMAB. However, 34 reports have been filed with the FAERS database.

What Other Side Effects Does TEZEPELUMAB Cause?

Asthma (204) Dyspnoea (170) Pneumonia (140) Death (92) Cough (87) Wheezing (83) Drug ineffective (81) Fall (47) Fatigue (47) Arthralgia (41)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which TEZEPELUMAB Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

TEZEPELUMAB vs TEZEPELUMAB-EKKO TEZEPELUMAB vs THALIDOMIDE TEZEPELUMAB vs THALOMID TEZEPELUMAB vs THEOPHYLLINE TEZEPELUMAB vs THEOPHYLLINE ANHYDROUS

Related Pages

TEZEPELUMAB Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease TEZEPELUMAB Demographics